To date, therapies aimed at enhancing granulopoiesis during sepsis, including the use of myeloid-specific growth factors, such as granulocyte-colony stimulating factor (G-CSF) and granulocyte/macrophage colony-stimulating factor (GM-CSF), have not proven effective in improving the survival of septic infants [42]. This evidence concerns the gene CSF3 and Sepsis.